NCT00539864View on ClinicalTrials.gov

Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

PHASE3CompletedINTERVENTIONAL
Enrollment

602

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Influenza
Interventions
BIOLOGICAL

FluBlok Influenza Vaccination

0.5mL dose for intramuscular injection

BIOLOGICAL

TIV (Fluzone) Influenza Vaccination

0.5mL dose for intramuscular injection

Trial Locations (5)

93726

Kaiser Permanente Pediatric Clinic - Fresno, Fresno

94545

Kaiser Permanente Pediatric Clinic - Hayward, Hayward

95661

Kaiser Permanente Pediatric Clinic - Roseville, Roseville

95823

Kaiser Permanente Pediatric Clinic - Sacramento, Sacramento

96814

Kaiser Permanente, Honolulu

All Listed Sponsors
lead

Protein Sciences Corporation

INDUSTRY

NCT00539864 - Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV | Biotech Hunter | Biotech Hunter